Table 2.
Total costs, QALYs, and cost-effectiveness at 10 year follow-up by patient subgroup
| Total cost (£) |
QALYs |
|||||||
|---|---|---|---|---|---|---|---|---|
| SITA | BITA | BITA vs. SITA Mean difference (95% CI, P-value) | SITA | BITA | BITA vs. SITAa Mean difference (95% CI, P-value) | ICER | Pr CE | |
| No history of diabetes (n = 2368) | 16 202 | 16 803 | 601 (–453, 1656); 0.251) | 6.67 | 6.61 | −0.032 (−0.19, 0.13; 0.688) | Dominatedb | 34% |
| Diabetes (n = 734) | 17 315 | 20 105 | 2790 (1064, 4516; 0.003) | 6.23 | 6.32 | 0.061 (−0.35, 0.47; 0.760) | 45 642 | 39% |
| Aged <70 years (n = 2271) | 15 276 | 16 563 | 1287 (576, 1998; 0.001) | 6.76 | 6.78 | 0.018 (−0.16, 0.19; 0.836) | 72 840 | 39% |
| Aged ≥70 years (n = 831) | 19 601 | 20 495 | 894 (–1282, 3070; 0.402) | 6.06 | 5.89 | −0.135 (−0.44, 0.17; 0.365) | Dominatedb | 14% |
| Off-pump (n = 1259) | 17 204 | 17 639 | 435 (–578, 1448; 0.379) | 6.51 | 6.52 | 0.027 (−0.20, 0.26; 0.805) | 13 903 | 51% |
| On-pump (n = 1819) | 16 067 | 17 781 | 1714 (297, 3130; 0.020) | 6.65 | 6.64 | −0.002 (−0.21, 0.21; 0.986) | Dominatedb | 32% |
| No prior MI (n = 1800) | 16 410 | 16 898 | 488 (–655, 1631; 0.387) | 6.65 | 6.65 | 0.026 (−0.18, 0.23; 0.794) | 18 903 | 49% |
| Prior MI (n = 1300) | 16 534 | 18 591 | 2057 (686, 3428; 0.005) | 6.46 | 6.38 | −0.079 (−0.28, 0.12; 0.430) | Dominatedb | 19% |
| NYHA class I and II (n = 2431) | 16 451 | 17 237 | 786 (–102, 1674; 0.080) | 6.64 | 6.70 | 0.071 (−0.08, 0.22; 0.338) | 11 496 | 56% |
| NYHA class III and IV (n = 669) | 16 494 | 18 839 | 2346 (51, 4640; 0.046) | 6.29 | 6.01 | −0.290 (−0.57, −0.01; 0.044) | Dominatedb | 15% |
| CCS class 0, I, II (n = 2143) | 16 565 | 16 938 | 372 (–742, 1486; 0.497) | 6.65 | 6.67 | 0.046 (−0.13, 0.22; 0.592) | 8758 | 56% |
| CCS class III, IVa/b/c (n = 959) | 16 225 | 19 029 | 2805 (898, 4711; 0.006) | 6.40 | 6.27 | −0.132 (−0.42, 0.16; 0.353) | Dominatedb | 20% |
| UK (n = 2053) | 17 173 | 18 181 | (−439, 2476; 0.154) 1008 (–385, 2402; 0.141) | 6.40 | 6.40 | 0.024 (−0.19, 0.24; 0.810) | 42 481 | 40% |
| Poland (n = 606) | 14 615 | 15 623 | (−72, 2084; 0.061) 1007 (–65, 2080; 0.060) | 6.79 | 6.96 | 0.202 (−0.06, 0.46; 0.091) | 4986 | 65% |
| Australia (n = 192) | 18 430 | 18 948 | (−2073, 3240; 0.665) 518 (–2165, 3202; 0.704) | 6.59 | 6.54 | −0.058 (−0.65, 0.53; 0.846) | Dominatedb | 39% |
a
Estimated differences in QALYs are adjusted for baseline EQ-5D-3L index.
b
BITA is more expensive but less effective.